David Miklos, MD, Stanford University

David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.

David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.